WO2026053081 - STABLE CANNABIDIOL ORAL FORMULATIONS
National phase entry is expected:
Publication Number
WO/2026/053081
Publication Date
12.03.2026
International Application No.
PCT/IB2025/058737
International Filing Date
29.08.2025
Title **
[English]
STABLE CANNABIDIOL ORAL FORMULATIONS
[French]
FORMULATIONS ORALES DE CANNABIDIOL STABLES
Applicants **
A2W PHARMA LIMITED
Inventors
MIZZI, John Paul
GURRADO, Domenico
Priority Data
18/827,370
06.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2082 | |
| EPO | Filing, Examination, Granting | 9134 | |
| Japan | Filing, Examination, Granting | 2214 | |
| South Korea | Filing, Examination, Granting | 2197 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
21,567
Contact Us
Abstract[English]
A stable oral composition comprising of: a) Cannabidiol; b) DL-α tocopherol; c) a cosolvent selected from Diethylene glycol mono ethyl ether (Transcutol-HPR) or the surfactant agent Lecithin; d) a synthetic sweetener; e) a flavoring agent and; f) Corn oil as a solvent. A stable oral composition comprising of (i) cannabidiol (CBD) at a concentration of from about 95 mg/ml to about 105 mg/ml, (ii) Diethylene glycol mono ethyl ether at a concentration from about 4.5 mg/ml to about 5.5 mg/ml or Lecithin at a concentration from about 0.45 mg/ml to about 0.55 mg/ml, (iii) DL-α tocopherol at a concentration from about 0.54 mg/ml to about 6.6 mg/ml, (iv) synthetic sweetener at a concentration from about 0.018 mg/ml to about 0.022 mg/ml, (v) Flavoring agent at a concentration from about 0.9 mg/ml to about 1.1 mg/ml, and (vi) corn oil q.s. to about 1.0 ml.[French]
L'invention concerne une composition orale stable comprenant : a) du cannabidiol ; b) du DL-α-tocophérol ; c) un cosolvant choisi parmi le monoéthyléther de diéthylène glycol (Transcutol-HPR) ou l'agent tensioactif lécithine ; d) un édulcorant synthétique ; e) un agent aromatisant et ; f) de l'huile de maïs en tant que solvant. Composition orale stable comprenant (i) du cannabidiol (CBD) à une concentration d'environ 95 mg/ml à environ 105 mg/ml, (ii) du monoéthyléther de diéthylène glycol à une concentration d'environ 4,5 mg/ml à environ 5,5 mg/ml ou de la lécithine à une concentration d'environ 0,45 mg/ml à environ 0,55 mg/ml, (iii) du DL-α-tocophérol à une concentration d'environ 0,54 mg/ml à environ 6,6 mg/ml, (iv) un édulcorant synthétique à une concentration d'environ 0,018 mg/ml à environ 0,022 mg/ml, (v) un agent aromatisant à une concentration d'environ 0,9 mg/ml à environ 1,1 mg/ml, et (vi) de l'huile de maïs qsp environ 1,0 ml.